NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

MS is currently treated with 'disease-modifying' medicines (e.g. interferon beta, glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate). These medicines can ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...

The team, consisting of researchers from University College London (UCL) and Queen Square Analytics, analysed 634 patients ...

Cold weather can significantly worsen multiple sclerosis symptoms, triggering stiffness, fatigue, and reduced mobility.

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.

Using artificial intelligence (AI), researchers looked at brain scans and tested for a blood marker for nerve cell injury and ...

England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Thousands of people in England with a type of multiple sclerosis (MS) are set to benefit from a new treatment on the NHS.